Skip to content

EPS (Basic) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+8.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.17-52.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$1.97+2,363%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$0.02-81.8%
AbbVie logo
AbbVieABBV
$0.39-45.8%
LBR
LB Pharmaceuticals Inc Common StockLBRX
-$0.67+95.5%

Other financials

Income statement

See full
Operating income-$64.5M-174%
Net income-$60.7M-172%
EPS (diluted)-$1.34+95.4%

Balance sheet

See full
Cash & equivalents$55.7M
Total debt$5.6M
Total equity$399.8M+285%
Total assets$418.8M

Cash flow

See full
Operating cash flow-$51.2M-100%
CapEx$24.0K
Free cash flow-$51.2M

Valuation

See full
Market cap$1.39B+109%
Enterprise value$1.34B

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio22.9×

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's eps (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's EPS (basic)?
MapLight Therapeutics, Inc. (MPLT) reported EPS (basic) of -$1.34 in Q1 2026.
How has MapLight Therapeutics, Inc. 's EPS (basic) changed year-over-year?
MapLight Therapeutics, Inc. 's EPS (basic) increased by 95.4% year-over-year, from -$29.33 to -$1.34.
What does EPS (basic) mean?
Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.